Pain Therapeutics
Pain Therapeutics
10th May to 11th May 2021,
London, United Kingdom
SMi presents its 21st annual Pain Therapeutics Conference, taking place in London on 10th and 11th May 2021. The global Postoperative Pain Therapeutics Market was valued at USD 11.26 Million in 2018 and is projected to reach USD 15.87 Million by 2026, growing at a CAGR of 4.40 % from 2019 to 2026. Chronic pain is a major health care problem that affects some 30%-50% of the world population and almost 20% of Europeans suffer from chronic or intermittent pain; the latter results in suffering and disability for patients and increasing economic loss for society.
The 21st Annual Conference will provide insights into cutting edge drug discovery science, preclinical development trends and will explore novel pain drug targets and novel biomarkers. Join Europe's leading Pain Therapeutics Conference which will analyse the latest developments in the field of pain drug development and learn how to industry is working to overcome the challenges of opioid base treatment.
source: http://www.smi-online.co.uk/pharmaceuticals/uk/conference/pain-therapeutics
If you have any questions about this news, please do not hesitate to contact us.
Join Our Newsletter for Free
Latest News
Vertex and CRISPR Therapeutics Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency to CTX001™ for Transfusion-Dependent Beta Thalassemia
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to CTX001, an investigational, autologous, ex vivo CRISPR/Cas9 gene-edited therapy for the treatment of transfusion-dependent beta thalassemia (TDT).
LEARN MOREPfizer Acquires Amplyx Pharmaceuticals
Pfizer Inc. (NYSE: PFE) announced today that it has acquired Amplyx Pharmaceuticals, Inc., a privately-held company dedicated to the development of therapies for debilitating and life-threatening diseases that affect people with compromised immune systems.
LEARN MOREJanux Therapeutics Closes $125 Million Series B Financing to Advance Next Generation T Cell Engager Immunotherapies into Clinical Trials
Janux Therapeutics today announced the closing of a $125 million Series B financing led by RA Capital Management and joined by new investors BVF Partners L.P., EcoR1 Capital, Hartford HealthCare Endowment, Janus Henderson Investors, Logos Capital, Samsara BioCapital and Surveyor Capital (a Citadel company).
LEARN MORE